VNDA has been in the news 1500% more than usual
Feb 23, 2026, 5:34 PM
0.00%
VNDA has been in the news recently: Vanda Pharmaceuticals (NASDAQ: VNDA) shares rose premarket Monday after the FDA approved Bysanti (milsaperidone) for bipolar I disorder and schizophrenia, even as U.S. stocks fell and the Dow dropped about 400 points. Over the last three months four analysts issued ratings on Vanda ranging from bullish to bearish, and some reports about the stock lacked full article detail (showing only the word "Gainers").
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.